Form 4 for IBRX ImmunityBio, Inc.
Accepted 2026-06-05 17:29:40 ET · period of report 2026-06-04 · accession 0001647994-26-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-06-05 17:29 | 2026-06-04 | IBRX | Simon Barry J. | Dir | S - Sale | $7.18 | -23.0K | 2.83M | -0.8% | -$165.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-04 | S | D | 23,033 | $7.18 | 2,827,788 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2025. (F2) Represents the weighted average share price of an aggregate total of 23,033 shares sold in the price range of $7.125 to $7.225 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. |